ISO 45002:2023 Internal Auditor Free Practice Test — 30 Questions

Question 1

MediCorp Innovations, a manufacturer of advanced diagnostic imaging equipment, recently launched a new MRI scanner. Following its release, post-market surveillance data reveals a higher-than-expected incidence of minor burns reported by patients during routine scans. Initial investigations suggest a potential issue with the scanner\'s radiofrequency (RF) coil design, leading to localized heating in certain patient demographics. According to ISO 13485:2016, which of the following actions represents the MOST comprehensive and compliant response to this situation, ensuring both patient safety and adherence to the standard\'s requirements for risk management and post-market surveillance? Assume that MediCorp has already halted the distribution of the MRI scanner. Consider all aspects of the QMS requirements, including documented information and supplier relations, as the RF coil is sourced from a third-party supplier. This also involves regulatory requirements, as burns are considered adverse events.

Accepted Answer

Conduct a thorough root cause analysis of the RF coil design, implement corrective actions to mitigate the burn risk, update the risk management documentation to reflect the new findings, communicate the issue and corrective actions to relevant regulatory bodies and the supplier of the RF coil, and monitor the effectiveness of the changes through continued post-market surveillance.

Question 2

BioSynth Medical, a manufacturer of implantable cardiac devices, has been marketing their new generation leadless pacemaker for 18 months. Initial risk assessments during design and development identified potential risks associated with battery life and migration of the device within the heart. Post-market surveillance data, gathered through physician feedback and patient registries, indicates a higher-than-anticipated rate of premature battery depletion in a subset of patients with specific pre-existing conditions not fully represented in the initial clinical trials. Furthermore, there have been a few reported instances of device migration requiring surgical intervention. According to ISO 13485:2016 requirements, what is the MOST appropriate and comprehensive action BioSynth Medical should take in response to this post-market data?

Accepted Answer

Conduct a reactive risk analysis integrating the post-market data, update the risk assessment documentation, review and potentially revise the design and development process, implement corrective actions, and enhance the post-market surveillance system.

Question 3

MedTech Solutions Inc., a manufacturer of implantable cardiac pacemakers certified under ISO 13485:2016, has observed a statistically significant increase in reported adverse events related to a newly introduced feature designed to enhance battery life. Post-market surveillance data indicates that patients with this feature are experiencing a higher rate of device malfunctions compared to the previous model without the feature. The Chief Quality Officer, Dr. Anya Sharma, convenes a meeting with the risk management team to address this issue. Considering the requirements of ISO 13485:2016 and the principles of risk management, what is the MOST appropriate immediate action for MedTech Solutions Inc. to take in response to this trend?

Accepted Answer

Initiate a formal risk assessment focused on the specific feature, re-evaluating existing risk controls and implementing corrective actions based on the assessment's findings.

Question 4

MedTech Solutions, a manufacturer of implantable cardiac pacemakers certified to ISO 13485:2016, has decided to switch from a manual soldering process to an automated robotic soldering system for attaching critical electronic components to the device\'s circuit board. The original manual process was meticulously validated, and a comprehensive risk assessment was performed. However, the engineering team believes the new automated system is inherently more precise and reliable, potentially reducing soldering defects. According to ISO 13485:2016, what is the MOST appropriate action MedTech Solutions should take regarding risk management and validation BEFORE implementing the automated soldering system?

Accepted Answer

Conduct a new risk assessment specifically focused on the potential hazards introduced by the automated soldering process, and then validate the automated process based on the outcomes of this risk assessment, ensuring that any new or modified risk controls are effectively verified.

Question 5

MedTech Solutions Inc., a manufacturer of Class II medical devices, is undergoing an internal audit to ensure compliance with ISO 13485:2016. The internal auditor, Anya Sharma, is reviewing the company\'s risk management processes, particularly focusing on the integration of post-market surveillance data. Anya discovers that while MedTech Solutions Inc. diligently collects post-market data through customer complaints, adverse event reports, and field safety corrective actions (FSCAs), this data is primarily used for regulatory reporting purposes. The data is not systematically analyzed to identify trends or emerging risks, nor is it formally integrated back into the risk management process to update risk assessments or refine risk control measures. The company\'s risk management file remains largely unchanged since the initial product launch, and there is no documented procedure for how post-market data should inform risk management activities.

Considering the requirements of ISO 13485:2016, what is the MOST significant deficiency in MedTech Solutions Inc.\'s approach to risk management and post-market surveillance?

Accepted Answer

The lack of a systematic process for analyzing post-market data to identify trends, emerging risks, and subsequently updating the risk management file and risk control measures, demonstrating a failure to close the feedback loop between post-market surveillance and risk management as required by ISO 13485:2016.

Question 6

MediCorp, a medical device manufacturer, discovers a potential safety issue with one of its Class II devices following post-market surveillance data analysis. This issue could lead to device malfunction under specific usage conditions, potentially causing harm to patients. As the internal auditor tasked with evaluating MediCorp\'s compliance with ISO 13485:2016, which of the following actions should MediCorp prioritize *initially*, considering the requirements for risk management, post-market surveillance, and regulatory compliance? This device is already released into the market and being used by patients. The potential malfunction has been identified but not yet confirmed as directly causing harm. The company is under pressure to act swiftly but also responsibly. Evaluate the options based on the immediate need to understand the scope and impact of the issue within the framework of a compliant QMS.

Accepted Answer

Initiate a formal risk assessment process to analyze the potential hazards, probability of occurrence, and severity of harm associated with the device malfunction, documenting the entire process.

Question 7

MedTech Solutions, a manufacturer of Class II medical devices, recently transitioned to ISO 13485:2016. During an internal audit, it was discovered that while all production and testing records are stored digitally on a centralized server, there are no specific user access controls in place. All employees have full read/write access to all records. Furthermore, the system lacks version control, and there is no audit trail to track who accessed or modified which records. The internal audit team also noted that there is no formal procedure for periodic review of these digital records to ensure their continued accuracy and integrity. Considering the requirements of ISO 13485:2016 regarding documented information and the control of records, which of the following corrective actions is MOST appropriate for MedTech Solutions to implement to address this nonconformity and ensure compliance?

Accepted Answer

Implement a comprehensive digital record management system with user access controls, version control, audit trails, and procedures for periodic review to ensure record integrity and compliance with ISO 13485:2016.

Question 8

Dr. Anya Sharma, the lead internal auditor for MedTech Solutions, a manufacturer of Class III implantable medical devices, is planning the annual internal audit program. MedTech Solutions\' QMS is certified to ISO 13485:2016. Considering the integrated approach to risk management required by the standard, which of the following strategies should Dr. Sharma prioritize to ensure the audit effectively assesses the implementation and effectiveness of risk management across MedTech Solutions\' QMS? The audit team comprises personnel with varying levels of experience in quality management and regulatory compliance. The organization has recently faced increased scrutiny from regulatory bodies regarding post-market surveillance data.

Accepted Answer

Define the audit scope to specifically include design and development, production and service provision, and post-market surveillance processes, ensuring the audit criteria are aligned with ISO 14971 and the organization's risk management plan, and ensure the audit team possesses competence in risk management principles and techniques.

Question 9

MedTech Solutions, a manufacturer of Class II medical devices, is undergoing an internal audit of their ISO 13485:2016-compliant Quality Management System (QMS). During the audit, Ingrid, the lead auditor, observes that while the design and development phase has a comprehensive risk management plan, there\'s limited evidence of risk assessment activities being consistently applied across other areas of the QMS, particularly in production, post-market surveillance, and supplier management. Documentation shows that risk assessments are performed during the initial design phase, but subsequent modifications to manufacturing processes and changes in supplier performance are not systematically evaluated for potential risks. Furthermore, post-market data analysis focuses primarily on addressing immediate complaints without proactively identifying potential systemic risks. Considering the requirements of ISO 13485:2016, what is the most significant nonconformity Ingrid should highlight in her audit report regarding risk management?

Accepted Answer

Inadequate integration of risk management throughout the QMS, leading to inconsistent application of risk assessment principles across all stages of the medical device lifecycle, including production, post-market surveillance, and supplier management.

Question 10

MediCorp, a manufacturer of implantable medical devices, is undergoing its transition to ISO 13485:2016. One of their critical components, the BioFuse Connector, is sourced from ConnectTech, a supplier known for inconsistent quality. MediCorp currently performs basic incoming inspections of the BioFuse Connectors but has not conducted a comprehensive assessment of ConnectTech\'s Quality Management System (QMS) or the potential risks associated with the connector\'s performance within MediCorp\'s final product. During an internal audit, a significant nonconformity is identified related to inadequate supplier control and oversight of outsourced processes. Considering the requirements of ISO 13485:2016, which of the following actions would be the MOST effective immediate corrective action to address this nonconformity and ensure compliance with the standard, while also mitigating potential risks associated with the BioFuse Connector?

Accepted Answer

Conduct a thorough risk assessment of ConnectTech's QMS and its impact on the BioFuse Connector, followed by the development and implementation of a comprehensive quality agreement outlining specific requirements for process control, testing, documentation, and performance monitoring.

Question 11

MedTech Solutions, a manufacturer of Class II medical devices, is undergoing an internal audit to assess their compliance with ISO 13485:2016. The internal audit team, led by Aaliyah, observes that while the company has meticulously documented risk management activities during the design and development phase of their new infusion pump, there is limited evidence of risk assessment being applied to their post-market surveillance processes, supplier management activities, and production line operations. Production personnel state they follow standard operating procedures (SOPs) but are unaware of the underlying risk assessments that informed those procedures. Supplier quality agreements lack specific clauses addressing risk mitigation responsibilities. Post-market data is collected, but not systematically analyzed for potential risks or trends. Aaliyah must determine the extent of the nonconformity. What is the most accurate conclusion regarding MedTech Solutions\' adherence to ISO 13485:2016 concerning risk management?

Accepted Answer

MedTech Solutions demonstrates a partial implementation of ISO 13485:2016 by addressing risk management during design and development, but fails to meet the standard's requirements for a comprehensive, organization-wide risk-based approach integrated into all QMS processes, including post-market surveillance, supplier management, and production.

Question 12

MedTech Innovations, a manufacturer of implantable cardiac devices, identified a biocompatibility issue with a polymer used in the device\'s housing through post-market surveillance data. The issue could potentially lead to adverse tissue reactions in a small percentage of patients. The design engineering team implemented a design change, substituting the original polymer with a newly formulated biocompatible material. According to ISO 13485:2016 requirements for Design History Files (DHF), what specific actions must MedTech Innovations undertake to ensure the DHF accurately reflects this design change and demonstrates compliance?

Accepted Answer

Update the design inputs to reflect the new biocompatibility requirements, modify the design outputs to incorporate the design changes, perform verification and validation activities to confirm that the change addresses the biocompatibility issue without introducing new risks, and document the entire process, including impact assessment and approval, within the DHF.

Question 13

MedTech Solutions, a manufacturer of Class II medical devices, is facing increasing challenges with product non-conformities detected during final inspection. These non-conformities are primarily attributed to inconsistent quality of a critical component sourced from a long-term supplier, Global Components Inc. Internal investigations reveal that while a quality agreement exists between MedTech Solutions and Global Components Inc., it lacks specific, measurable performance indicators and a robust system for monitoring supplier performance and addressing non-conformities. As the internal auditor tasked with evaluating the effectiveness of MedTech Solutions\' QMS according to ISO 13485:2016, which of the following recommendations would most effectively address the identified weaknesses and enhance risk management related to supplier quality?

Accepted Answer

Revise the quality agreement with Global Components Inc. to include specific, measurable performance indicators, implement a system for regular monitoring of supplier performance, and establish a clear process for addressing non-conformities, including root cause analysis and corrective actions, to mitigate risks associated with supplier quality.

Question 14

MedTech Solutions Inc., a manufacturer of Class II medical devices, is transitioning its Quality Management System (QMS) to comply with ISO 13485:2016. Dr. Anya Sharma, the newly appointed internal audit manager, is tasked with developing a comprehensive internal audit program. Given the company\'s aim to achieve certification within the next year and its existing ISO 9001 certification, which of the following approaches should Dr. Sharma prioritize to ensure the internal audit program effectively assesses compliance and drives continuous improvement within the framework of ISO 13485:2016, considering the specific regulatory requirements for medical devices in both the US (FDA) and Europe (EU MDR)? The internal audit program must not only verify conformance but also identify opportunities for enhancing the QMS to meet the stringent demands of the medical device industry.

Accepted Answer

Implement a risk-based audit approach that focuses on assessing the effectiveness of risk management processes throughout the QMS, including design and development, production, post-market surveillance, and supplier controls, ensuring alignment with regulatory requirements such as FDA 21 CFR Part 820 and EU MDR, and verifying the competence of personnel involved in these processes.

Question 15

\"MediTech Solutions,\" a manufacturer of Class II medical devices, is undergoing an internal audit as part of their transition to ISO 13485:2016. The audit team, led by senior auditor Anya Sharma, has identified inconsistencies in how different departments interpret and apply the requirements related to the \"context of the organization.\" The marketing department primarily focuses on customer needs and market trends, while the regulatory affairs department concentrates on compliance with FDA regulations and EU MDR requirements. The production team, on the other hand, is mainly concerned with operational efficiency and minimizing production costs. Anya recognizes that this siloed approach could lead to a fragmented QMS and potential nonconformities. To address this issue effectively and ensure a holistic understanding of the context of the organization, what specific action should Anya recommend to top management as a priority?

Accepted Answer

Implement a cross-functional workshop involving representatives from all relevant departments to collaboratively identify and document all internal and external factors impacting the QMS, define the needs and expectations of all interested parties, and establish a clear, unified scope for the QMS that aligns with the organization's strategic objectives and regulatory requirements.

Question 16

\"MediCorp Solutions,\" a multinational medical device manufacturer, is transitioning to ISO 13485:2016. During an internal audit, the audit team, led by senior auditor Astrid, discovers that while the organization has a comprehensive risk management process for product design and development, the risk management activities related to supplier selection and monitoring are limited to basic financial solvency checks and adherence to delivery schedules. There is a lack of formal risk assessment concerning the quality management systems of critical suppliers, their ability to consistently meet regulatory requirements, and the potential impact of supplier-related issues on the safety and performance of MediCorp\'s devices. Considering the requirements of ISO 13485:2016, what is the most significant gap in MediCorp\'s current approach to risk management, and what specific actions should Astrid recommend to address this gap to ensure compliance and enhance product safety?

Accepted Answer

The inadequate integration of risk management into supplier selection and monitoring processes, requiring the implementation of formal risk assessments of supplier quality management systems, regulatory compliance, and potential impact on device safety and performance, including the establishment of quality agreements with suppliers outlining risk mitigation strategies and performance monitoring metrics.

Question 17

MediTech Solutions, a medical device manufacturer, is undergoing an internal audit as part of its transition to ISO 13485:2016. The audit team, led by senior auditor Anya Sharma, identifies that the company has meticulously documented its design verification process, demonstrating that design outputs consistently meet design inputs through rigorous testing and analysis. However, the audit reveals a significant gap in the design validation process. While design inputs are well-defined, there is limited objective evidence to demonstrate that the final medical devices consistently meet the intended clinical needs and user requirements in real-world scenarios. Documentation of clinical evaluations is sparse, user feedback mechanisms are underdeveloped, and validation protocols lack sufficient detail. Given these findings and considering the requirements of ISO 13485:2016, what should Anya Sharma recommend as the *most critical* corrective action to ensure compliance and improve the effectiveness of MediTech Solutions\' Quality Management System (QMS)?

Accepted Answer

Enhance the design validation process by developing robust validation protocols, conducting comprehensive clinical evaluations, gathering user feedback, and documenting all validation activities to ensure devices meet intended clinical needs.

Question 18

MediTech Innovations, a manufacturer of Class II medical devices, is in the midst of transitioning its Quality Management System (QMS) to ISO 13485:2016. During an internal audit, several concerns were raised regarding the performance of key suppliers and the control of outsourced processes, particularly sterilization. Some suppliers are consistently late with deliveries of critical components, and the outsourced sterilization process has shown occasional deviations from established parameters. The CEO, Alisha Kapoor, is concerned about potential disruptions to production and the impact on product quality. Alisha seeks your advice, as the lead internal auditor, on the most appropriate immediate action to address these concerns in alignment with ISO 13485:2016 requirements. Considering the emphasis on risk management and supplier control within the standard, what should be the initial step taken by MediTech Innovations to address these supplier and outsourcing issues?

Accepted Answer

Conduct a comprehensive risk assessment of the existing supplier and outsourced processes, focusing on potential impacts to product quality and regulatory compliance, and then implement appropriate mitigation strategies.

Question 19

A medical device company, \"MediCorp Solutions,\" is certified to ISO 13485:2016. An internal auditor, Anya Sharma, is assigned to conduct an audit of the supplier management processes. During her preparation, Anya realizes that she previously worked as a consultant for \"Precision Components Inc.,\" one of MediCorp\'s critical suppliers of a key component used in their Class III implantable devices. As a consultant, Anya helped Precision Components Inc. to improve their manufacturing processes and prepare for their ISO 13485 certification audit two years prior. Anya is now responsible for evaluating Precision Components Inc.\'s performance and compliance with MediCorp\'s quality management system. According to ISO 45002:2023 guidance on internal auditing in the context of ISO 13485:2016, what is the MOST appropriate course of action for Anya to take in this situation to ensure the integrity and objectivity of the audit process, considering the potential conflict of interest?

Accepted Answer

Disclose the prior relationship with Precision Components Inc. to the audit program manager or quality management representative at MediCorp Solutions immediately.

Question 20

MedTech Solutions, a manufacturer of Class II medical devices, is undergoing its first internal audit since transitioning to ISO 13485:2016. During the audit, Ingrid, the lead auditor, discovers that while the design and development department has meticulously documented risk management activities according to ISO 14971, other departments, such as production and supplier management, have limited or no documented risk assessments. Production primarily relies on standard operating procedures (SOPs) to control processes, and supplier selection is based mainly on cost and delivery time, with minimal consideration of quality risks. Post-market surveillance data is collected but not systematically analyzed for potential risks. According to ISO 45002:2023 guidance on auditing ISO 13485:2016, what is Ingrid\'s MOST significant finding regarding the implementation of risk management within MedTech Solutions\' QMS?

Accepted Answer

The organization has not adequately integrated risk management principles throughout the QMS, focusing primarily on design and development, which is a deviation from the holistic risk-based approach required by ISO 13485:2016.

Question 21

Dr. Anya Sharma is leading the internal audit team at MedTech Innovations, a manufacturer of Class III implantable medical devices. During a recent audit, the team observed that while MedTech Innovations had implemented a robust risk management process according to ISO 14971 for device safety, risk management principles were not consistently applied across all processes within their ISO 13485:2016 compliant Quality Management System (QMS). Specifically, the audit revealed a lack of documented risk assessments related to supplier selection, process validation, and change control. Considering the requirements of ISO 13485:2016, what is the MOST accurate interpretation of this finding?

Accepted Answer

MedTech Innovations needs to integrate risk management into all QMS processes, including supplier selection, process validation, and change control, to align with ISO 13485:2016 requirements.

Question 22

MediCorp, a medical device manufacturer, is undergoing a transition to ISO 13485:2016. During an internal audit, several nonconformities were identified related to the integration of risk management within their Quality Management System (QMS). Specifically, the audit revealed that risk analysis during the design input phase is not comprehensive, leading to potential hazards being overlooked. This has resulted in increased design changes later in the development cycle and recurring issues identified through post-market surveillance. The management team acknowledges the need for improvement but is unsure of the most effective approach. Considering the requirements of ISO 13485:2016 and the need to proactively address risks throughout the product lifecycle, which of the following actions would MOST effectively improve MediCorp\'s compliance and address the identified shortcomings in risk management integration within their QMS?

Accepted Answer

Implement a formal, prospective risk analysis methodology (e.g., FMEA, Hazard Analysis) during the design input stage to systematically identify and mitigate potential hazards associated with design requirements and intended use.

Question 23

MedTech Solutions, a manufacturer of implantable cardiac pacemakers, is preparing for an internal audit focused on their Quality Management System (QMS) as per ISO 13485:2016. During a review of their documented information procedures, the internal audit team, led by Aaliyah, discovers inconsistencies in the document control process across different departments. Specifically, the design engineering department uses a cloud-based system with automated version control, while the production department relies on a manual system of printed documents and revision logs. The CAPA (Corrective and Preventive Action) department has a hybrid system, using electronic records for new CAPAs but maintaining paper files for older ones. Aaliyah is concerned that these disparate systems may not adequately meet the requirements of ISO 13485:2016, particularly regarding the control of documents and records. Which of the following actions should Aaliyah recommend to ensure MedTech Solutions achieves and maintains compliance with ISO 13485:2016 regarding documented information?

Accepted Answer

Implement a unified, validated electronic document management system (EDMS) across all departments, ensuring that all documented information, including documents and records, is controlled, readily accessible, and protected against unauthorized changes or loss, with clearly defined retention periods and disposal procedures, and provide training to all personnel on the new system.

Question 24

MediCorp Innovations, a medical device manufacturer, is transitioning its Quality Management System (QMS) to ISO 13485:2016. During an internal audit, a nonconformity is identified related to a critical component sourced from a new supplier. The initial supplier selection process included a risk assessment, but post-market surveillance data indicates significant variability in the component\'s performance, potentially affecting the final device\'s safety and effectiveness. The audit reveals that there are no documented procedures for addressing component performance variability, and the link between post-market data and the supplier monitoring process is weak. Considering the requirements of ISO 13485:2016 regarding risk management and supplier control, what is the MOST appropriate immediate action that MediCorp Innovations should take to address this nonconformity?

Accepted Answer

Conduct a thorough review and update of the risk assessment, incorporating the potential impact of component variability identified through post-market surveillance, and use this to inform the supplier monitoring process.

Question 25

BioTech Solutions, a manufacturer of implantable cardiac pacemakers, is transitioning from ISO 13485:2003 to ISO 13485:2016. During the initial gap analysis, the internal audit team identifies that while the company has a documented risk management procedure, it is primarily applied only during the design and development phase of new products. Production processes, supplier selection, and post-market surveillance activities have limited integration of formal risk assessment methodologies. The CEO, Alisha, is committed to a smooth transition and wants to ensure full compliance with the new standard. Which of the following represents the MOST critical and immediate action BioTech Solutions should take to address this gap and align its QMS with the requirements of ISO 13485:2016 regarding risk management?

Accepted Answer

Develop and implement a comprehensive plan to integrate risk management principles and practices into all relevant processes of the QMS, including production, supplier management, post-market surveillance, and CAPA, ensuring documented evidence of risk assessments and mitigation strategies throughout the product lifecycle.

Question 26

MedTech Solutions, a manufacturer of implantable cardiac devices, is undergoing an internal audit to assess its compliance with ISO 13485:2016. The audit team, led by senior auditor Anya Sharma, is reviewing the company\'s risk management processes. During the audit, Anya discovers that while MedTech Solutions has conducted thorough risk assessments during the design and development phase of their new pacemaker, there is limited evidence of ongoing risk management activities related to post-market surveillance. Specifically, the audit reveals that customer complaints related to battery life are not systematically analyzed for potential safety risks, and there is no formal process for trending adverse events reported through vigilance systems. Furthermore, design changes implemented to address manufacturing inefficiencies were not subjected to a formal risk assessment to evaluate their potential impact on product safety and performance. Considering the requirements of ISO 13485:2016, which of the following represents the most significant nonconformity related to risk management at MedTech Solutions?

Accepted Answer

Insufficient integration of risk management principles into the QMS, particularly concerning post-market surveillance, vigilance reporting, and the risk assessment of design changes.

Question 27

MedTech Solutions, a well-established manufacturer of Class II medical devices, is undergoing the transition from ISO 13485:2003 to ISO 13485:2016. During an internal audit, several gaps are identified in their current QMS. Specifically, the audit team, led by senior auditor Anya Sharma, notes that the company\'s risk management processes are not fully integrated into all areas of the QMS, documented information is not consistently controlled across different departments, and post-market surveillance activities are primarily reactive, relying on customer complaints rather than proactive data collection. Furthermore, there is limited evidence of a comprehensive understanding of the needs and expectations of all interested parties beyond direct customers. The management team, headed by CEO Javier Rodriguez, is concerned about the potential impact of these gaps on their upcoming external audit and their ability to maintain regulatory compliance, particularly with the EU Medical Device Regulation (MDR). Considering the requirements of ISO 13485:2016, what should be MedTech Solutions\' *MOST* immediate and critical action to address these identified gaps and ensure a successful transition?

Accepted Answer

Implement a comprehensive plan to integrate risk management into all QMS processes, enhance the control of documented information, establish proactive post-market surveillance systems, and conduct a thorough analysis of the needs and expectations of all interested parties.

Question 28

BioTech Innovations, a manufacturer of implantable cardiac devices, implements a significant design change to its flagship pacemaker model to improve battery longevity. This change directly impacts the device\'s performance characteristics and has the potential to affect patient safety. As the lead internal auditor, you are tasked with evaluating the effectiveness of the company\'s change control process in accordance with ISO 13485:2016. Which of the following actions would BEST demonstrate compliance with the documented information requirements, design control procedures, and regulatory compliance obligations following the implementation of this design change?

Accepted Answer

Updating the Design History File (DHF) to include the design change details, ensuring all relevant documented information (e.g., design inputs, outputs, risk assessments, manufacturing procedures) are updated to reflect the change, and assessing the impact on existing regulatory filings, submitting notifications to regulatory bodies (e.g., FDA, EU MDR) if required.

Question 29

BioTech Solutions, a medical device manufacturer, is developing a novel implantable cardiac monitor. During the design and development phase, the engineering team encounters a challenge. Certain critical design outputs, specifically the signal processing algorithms that detect arrhythmias, cannot be fully verified through subsequent monitoring or measurement of the finished device due to the complexity of in-vivo conditions and patient variability. Standard testing protocols and simulation models provide limited insight into the real-world performance of these algorithms. According to ISO 13485:2016, considering this situation, what is the MOST appropriate course of action for BioTech Solutions to ensure compliance and product safety? The company needs to address the verification of the design outputs before proceeding to validation and market release. This situation is further complicated by upcoming audits related to compliance with the EU MDR.

Accepted Answer

Implement verification activities to confirm that the design outputs meet the design input requirements before product release.

Question 30

MediCorp Solutions, a manufacturer of implantable cardiac pacemakers, is undergoing a transition to ISO 13485:2016. As the internal audit team lead, you are tasked with evaluating the organization\'s understanding of the \"context of the organization\" requirement. During your assessment, you discover that MediCorp has primarily focused on meeting the regulatory requirements stipulated by the FDA and EU MDR, with limited consideration given to other stakeholders. The company\'s leadership believes that compliance with these regulations adequately addresses the needs of all interested parties. Furthermore, their current QMS scope is narrowly defined around their existing pacemaker product line, with minimal consideration for potential future product diversification or market expansion. What is the MOST appropriate recommendation to ensure MediCorp Solutions fully complies with the \"context of the organization\" requirement of ISO 13485:2016?

Accepted Answer

Conduct a comprehensive analysis of all relevant stakeholders (patients, healthcare providers, regulatory bodies, suppliers, employees) and their expectations related to product quality, safety, and regulatory compliance. This analysis should inform the scope of the QMS and the processes needed to meet these expectations.

ISO 45002:2023 Internal Auditor Free Practice Test — 30 Questions

The free lane is only the front row

How to Use This ISO 45002:2023 Internal Auditor Practice Test

About the ISO 45002:2023 Internal Auditor Practice Test

Practice Method for This Page

Frequently Asked Questions about ISO 45002:2023 Internal Auditor

Is this ISO 45002:2023 Internal Auditor practice test really free?

How many questions are on the real ISO 45002:2023 Internal Auditor exam?

What score should I target before scheduling?

Preparing for ISO 45002:2023 Internal Auditor? Now land the interview.

More Study Resources for ISO 45002:2023 Internal Auditor